Pacific Biosciences is trying to turn a cheaper long-read genome into a self-funding clinical franchise after years of burning cash on a short-read side bet that it has now sold. The second-quarter print is the first clean look at that reset: the Onso short-read assets are gone, SPRQ-Nx multi-use chemistry is in full commercial rollout, and the board replaced the chief executive on the same day it cut the year and pushed cash-flow breakeven out to calendar 2028. Revenue of $39 million was essentially flat. The debate is not whether HiFi reads are scientifically useful. It is whether utilization and mix can outrun a still-heavy cost base before cash and the convertible stack force another recapitalization.
What is actually moving is mix, not scale. Consumables rose even as instrument revenue fell, because Revio placements tilted toward new and clinical accounts while Vega shipments slowed under academic-funding pressure. Annualized Revio pull-through slipped to about $202 thousand as customers worked through old chemistry inventory before adopting the multi-use workflow. That is the SPRQ-Nx bargain in action: a lower list price per genome that only pays PacBio if labs run more samples. Clinical shipments grew fast and still represent only a mid-teens share of consumable volume, so the mix shift is real and still small.
The August results announcement also disclosed a workforce cut of about forty people and a plan to take thirty to forty million of annualized operating expense out by late 2027. Cash and investments stood at $237 million at mid-year. First-half operations consumed $80 million of cash, and stockholders' equity flipped to a deficit. Management now guides full-year revenue to a band whose midpoint is no higher than last year's print. The next several quarters decide whether SPRQ-Nx reorders and clinical production sequencing lift pull-through, or whether the chemistry transition simply cheaper-sells a still-sub-scale installed base.